ScRNA-seq profiles of surgical tumor specimens obtained from the first-in-human clinical trial of neoadjuvant nivolumab in resectable NSCLC (GSE176021) also demonstrated that memory and effector CD8 signatures were more enriched in tumor tissues that acquired MPR (Fig. 7b). Here, CD8A is linked to non-small cell lung carcinoma.